Spots Global Cancer Trial Database for A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Official Title: A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Study ID: NCT06067841
Interventions
Study Description
Brief Summary: The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Stanford Cancer Center, Palo Alto, California, United States
Florida Cancer Specialists Sarasota Drug Development Unit, Sarasota, Florida, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Duke Cancer Institute, Durham, North Carolina, United States
Local Institution - 0006, San Antonio, Texas, United States
NEXT Oncology, San Antonio, Texas, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
